论文部分内容阅读
目的:评估人重组内皮抑素(endostar,ES)辅助化疗药物治疗食管癌的临床效果。方法:研究共入组128例食管癌患者,根据化疗方案将患者分为试验组与对照组,试验组患者(n=60)进行5个疗程ES联合化疗,每个化疗疗程持续3周,静脉注射ES 15mg/d。对照组患者(n=68)未使用ES化疗。化疗2个疗程后,手术切除肿瘤,分析肿瘤对化疗的反应。检测血管内皮生长因子(vascular endothelial growth factor,VEGF)和血小板-内皮细胞粘附分子(Platelet endothelial cell adhesion molecule-1,CD31)的表达。结果:同治疗前比较,化疗明显促进了食管癌肿瘤组织中的VEGF的表达和组织中血管的再生。两组相比,试验组患者的生存率明显提高,转移率明显降低,通过重组内皮抑素治疗显著抑制了化疗引起的VEGF的表达和微血管的生成。结论:联合重组内皮抑素化疗能够显著改善食管癌患者的临床结局。
Objective: To evaluate the clinical effect of recombinant human endostar (ES) adjuvant chemotherapy on esophageal cancer. Methods: A total of 128 patients with esophageal cancer were enrolled. Patients were divided into experimental group and control group according to the chemotherapy regimen. Patients in the experimental group (n = 60) underwent 5 cycles of ES combined with chemotherapy. Each chemotherapy course lasts for 3 weeks. ES was injected 15 mg / d. Control patients (n = 68) did not receive ES chemotherapy. After 2 cycles of chemotherapy, the tumor was surgically removed and the response of the tumor to chemotherapy was analyzed. The expression of vascular endothelial growth factor (VEGF) and platelet endothelial cell adhesion molecule-1 (CD31) were detected. Results: Compared with those before treatment, chemotherapy significantly promoted the expression of VEGF and the regeneration of blood vessels in esophageal cancer tissues. Compared with the two groups, the survival rate in the experimental group was significantly increased, the metastasis rate was significantly reduced, and the treatment with recombinant endostatin significantly inhibited the VEGF-induced VEGF expression and microvascular formation. Conclusion: The combination of recombinant endostatin chemotherapy can significantly improve the clinical outcome of esophageal cancer patients.